Compare Inovio Pharmaceuticals Inc (INO) vs Stitch Fix Inc (SFIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Inovio Pharmaceuticals Inc vs Stitch Fix Inc — how do they compare? Inovio Pharmaceuticals Inc trades at $1.09 (market cap $89.27M), while Stitch Fix Inc trades at $3.83 (market cap $520.36M). The key difference: Stitch Fix Inc is far larger — about 5.8× Inovio Pharmaceuticals Inc's market cap, and Stitch Fix Inc is trading nearer its 52-week high, Inovio Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| INO | SFIX | |
|---|---|---|
Market Cap | $89.27M | $520.36M |
Sector | Health | Consumer Cyclical |
52-Week High | $2.87 | $5.83 |
52-Week Low | $1.05 | $3.06 |
Enterprise Value | $60.28M | $408.08M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INO trades at $1.07, down 4.46% today, reflecting persistent bearish technical signals. The company shows minimal revenue of $65.34K (2025) with a net loss of $84.95M, resulting in a negative net margin of 130,000%. Despite beating recent EPS estimates, cash flow remains negative. Key near-term catalyst is the FDA's PDUFA decision on INO-3107 by October 30, 2026.
Outlook hinges on regulatory success for INO-3107; approval could drive significant upside, but failure poses substantial risk. High cash burn and lack of profitability underscore speculative nature. Analyst consensus is cautiously optimistic with 53% buy ratings, yet financial health remains precarious without near-term revenue growth.
Stitch Fix (SFIX) trades at $3.935, up 3.83% on the day, showing signs of a potential turnaround with recent earnings beats and a bullish technical signal. The company reported a narrowed net loss in 2025, with revenue stabilizing at $1.27 billion and a gross margin of 43.66%. Analyst consensus is a $4.75 price target, though the stock remains near historic lows, presenting a value opportunity amid improving client metrics and AI-driven personalization efforts.
The outlook for SFIX hinges on sustained execution of its turnaround strategy, with risks including consumer spending pressure and competitive threats. Upside potential exists if margin improvements and active client growth continue, but investors should weigh the company's history of net losses against recent positive momentum and analyst caution, with 63.64% holding a neutral stance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →About Stitch Fix Inc
Stitch Fix Inc offers personal style service for men and women. The company engages in delivering one-to-one personalization to clients through the combination of data science and human judgment. It provides a shipment service called A FIX where the stylist's hand selects items from several merchandises with analysis of client and merchandise data to provide a personalized shipment of apparel, shoes, and accessories suited to the client's needs. The company offers products across categories, brands, product types and price points including Women's, Petite, Maternity, Men's and Plus. It also offers various product types, including denim, dresses, blouses, skirts, shoes, jewelry and handbags, and sells merchandise across various range of price points.
Read more on SFIX →
